Highlights,Mineralys Therapeutics' stock opened at $10.15, reflecting recent market adjustments.,Executive transactions ...
Q4 2024 Earnings Call Transcript February 12, 2025 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is ...
In a report released today, Richard Law CFA from Goldman Sachs maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research ...
Jon Congleton; Chief Executive Officer, Director; Mineralys Therapeutics Inc. David Rodman; Chief Medical Officer ...
MyChesCo on MSN1d
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for LorundrostatMineralys Therapeutics, Inc. (Nasdaq: MLYS) reported its financial results for the fourth quarter and full year ending ...
CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...
Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...
The co-extrusion of this demonstration coupon sample represents a key fabrication milestone under Lightbridge's Strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback